Mechanisms of tumor escape from immune destruction include evasive strategies to avoid immune recognition, as well as active modulation and suppression of immune cell function. The applicant's recent studies suggest that ovarian carcinoma (OvCA) cells are capable of activating an intrinsic mechanism of programmed cell-death in interacting T lymphocytes in situ and in vitro. The overall goal of the study is to delineate protective mechanisms that may have potential therapeutic use against inappropriate death of T lymphocytes at the tumor site. Based on the applicant's preliminary studies, she hypothesizes that death receptors expressed on tumor-associated lymphocytes (TAL) are activated to initiate an apoptotic cell death of the lymphocytes interacting with ovarian cancer cells. She further hypothesizes that the observed apoptotic cell death can be prevented by treatment with IL-2 or IL-12 cytokines, which upregulate activity of endogenous protective mechanisms against apoptosis of lymphocytes. To test this hypothesis, the following specific aims are proposed: (1) to investigate the role of death receptors on T cells in ovarian cancer-induced apoptosis of lymphocytes; (2) to identify the intracellular mechanisms of cell death activated in T lymphocytes interacting with ovarian cancer cells; (3) to identify endogenous and cytokine-induced anti-apoptotic mechanisms which can protect lymphocytes from ovarian cancer-induced apoptosis; (4) to investigate mechanisms of lymphocyte survival activated by intraperitoneal IL-2 or IL-12 therapy of patients with ovarian cancer, as a part of concurrent phase I/II clinical trials. These studies are expected to provide insights into the role played by death receptors on lymphocytes in immunosuppression mechanisms operated in OvCA. To develop an effective cancer therapy, it is important to elucidate what determines the susceptibility of lymphocytes to tumor-mediated cell death and what mechanisms are involved in their protection. An understanding of these mechanisms is essential for developing effective therapy regimens that would render infiltrating lymphocytes resistant to tumor-induced apoptosis and prevent or reverse the immune-hyporespsonsiveness seen in patients with OvCA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084134-03
Application #
6514266
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wu, Roy S
Project Start
2000-03-15
Project End
2004-02-29
Budget Start
2002-07-18
Budget End
2004-02-29
Support Year
3
Fiscal Year
2002
Total Cost
$240,931
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Han, J; Goldstein, L A; Gastman, B R et al. (2004) Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 18:1671-80
Han, Jie; Goldstein, Leslie A; Gastman, Brian R et al. (2004) Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 279:22020-9
Wieckowski, Eva; Wang, Gui-Qiang; Gastman, Brian R et al. (2002) Granzyme B-mediated degradation of T-cell receptor zeta chain. Cancer Res 62:4884-9
Wang, G Q; Wieckowski, E; Goldstein, L A et al. (2001) Resistance to granzyme B-mediated cytochrome c release in Bak-deficient cells. J Exp Med 194:1325-37
Wang, G Q; Gastman, B R; Wieckowski, E et al. (2001) A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 276:34307-17
Wang, G Q; Gastman, B R; Wieckowski, E et al. (2001) Apoptosis-resistant mitochondria in T cells selected for resistance to Fas signaling. J Biol Chem 276:3610-9
Gastman, B R; Yin, X M; Johnson, D E et al. (2000) Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade. Cancer Res 60:6811-7